Biocept Just Filed Its Quarterly Report: 10. Net Loss per Co...

10. Net Loss per Common Share

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the nine months ended September 30, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse stock split as if it had occurred on January 1, 2015.

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

 

 

 

For the three and nine months ended

 

 

September 30,

 

 

2015

 

 

2016

 

Preferred warrants outstanding (number of common stock equivalents)

 

529

 

 

 

529

 

Preferred share RSUs (number of common stock equivalents)

 

24,384

 

 

 

 

Common warrants outstanding

 

797,579

 

 

 

1,896,856

 

Common share RSUs

 

25,752

 

 

 

176,749

 

Common options outstanding

 

684,779

 

 

 

926,608

 

Total anti-dilutive common share equivalents

 

1,533,023

 

 

 

3,000,742

 

 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Biocept makes a similar move, sign up!

Other recent filings from the company include the following:

Amendments to Articles of Incorporation or - Sept. 29, 2017

Auto Refresh

Feedback